Excalibur Fund Manager
A £38 million fund fully invested in UK life science companies.
 | Ark Therapeutics Group plc Gene-based drugs for vascular and circulatory diseases and cancer IPO in February 2004. Fully disposed |
 | Biovex Group Inc Development and commercialisation of biological treatments for cancer and the prevention of infectious disease |
 | Cyclacel Pharmaceutical Inc Cell cycle control drugs for cancer IPO in January 2006. Fully disposed |
 | KinderTec Ltd Paediatric consumer healthcare products Trade sale in December 2005 |
 | Microscience Investments Ltd Vaccines for typhoid, travellers’ illnesses and hepatitis B Merged with NASDAQ listed Emergent Biosolutions Inc in July 2005 |
 | PanTherix Ltd Novel broad-spectrum antibiotics |
 | ReNeuron Group plc Treatments for neurological disorders IPO in August 2005 |
 | Vectura Group plc Drug formulations and devices for respiratory diseases IPO in July 2004. Fully disposed |
